🇺🇸 Liposomes in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 12

Most-reported reactions

1. Drug Interaction — 2 reports (16.67%)
2. Pulmonary Toxicity — 2 reports (16.67%)
3. Anaemia — 1 report (8.33%)
4. Bacterial Infection — 1 report (8.33%)
5. Blood Creatinine Increased — 1 report (8.33%)
6. Breath Sounds Abnormal — 1 report (8.33%)
7. Carbon Monoxide Diffusing Capacity Decreased — 1 report (8.33%)
8. Cholangitis — 1 report (8.33%)
9. Cholestasis — 1 report (8.33%)
10. Disseminated Mucormycosis — 1 report (8.33%)

Source database →

Frequently asked questions

Is Liposomes approved in United States?

Liposomes does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Liposomes in United States?

Kenneth Peters, MD is the originator. The local marketing authorisation holder may differ — check the official source linked above.